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Abstract: 
Nausea and vomiting are the most distressing and common side effects of cancer 
chemotherapy which often result in patient non-compliance. In the present study, 
standardized methanolic fractions of Bacopa monniera (BM) were evaluated against cisplatin 
induced emesis in the pigeon in relation to their activity on central and intestinal 
neurotransmitter levels. 
Cisplatin (7.0 mg/kg, i.v.) induced reproducible emesis without lethality in healthy pigeons. The 
methanolic (10±40 mg/kg), the bacoside rich n-butanolic fractions of B. monniera (5±20 
mg/kg) as well as the antioxidant N-(2-Mercaptoprpionyl) glycine (10 mg/kg) attenuated 
cisplatin induced emesis by 66.3% (P<0.05), 71.6% (P<0.001) and 76.5%  (P<0.001), 
respectively; where the standard antiemetic, metoclopramide (30 mg/kg), produced a 48.9% 
reduction (P<0.01). 
The methanolic and n-butanolic fractions of B. monniera at all of the doses tested 
significantly reduced  the serotonin concentration (P<0.001) in the brain stem and intestine 3 
h after cisplatin administration, while at the 18th hour, B. monniera  treatments attenuated not 
only the dopamine upsurge in the area postrema and brain stem (P<0.05-0.001), but also the 
intestinal 5-HT concentration (P<0.01-0.001). B. monniera treatments alone did not alter the 
basal neurotransmitters or their metabolites in the brain areas and intestine.  
The prolonged suppressive effect of BM treatments on the behavioral signs of cisplatin-    
induced emesis, the subsequent supportive neural evidence and the safety and tolerability 
profile suggest that B. monniera  methanolic and bacoside rich n-butanolic fractions might be 
a valuable adjunct in the treatment of emetogenic chemotherapy and this warrants further 
study in other models of emesis. 
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1. Introduction: 
Nausea and vomiting induced by chemotherapeutic agents like cisplatin are accepted as the 
most distressing adverse effects of cancer chemotherapy[1,2]. These side effects often result 
in poor patient compliance and if not satisfactorily controlled, can lead to refusal of treatment 
[3]. The older classes of antiemetics including antagonists at histamine, dopamine, and 
muscarinic receptors exhibit only modest effects against chemotherapy emetogenesis. In 
addition, these antiemetics also possess their own inherent assortment of unpleasant side 
effects [4]. 
The development of 5-HT3 receptor antagonists subsequently revolutionized the treatment of 
chemotherapy induced vomiting (CIV), and interestingly, an acute (day 1) and delayed (post 
day 1) biphasic nature of their activities has been perceived. Unfortunately, approximately 10 
± 30% of patients are unprotected by 5-HT3 receptor antagonists [5], the delayed phase of 
vomiting being the most poorly controlled [6]. Tachykinin NK1 receptor antagonists, such as 
aprepitant, have a wider spectrum of antiemetic action than the older classes of drugs, are 
now being used in combination with 5-HT3 receptor antagonists and co-administered with 
glucocorticoids to control emetogenic chemotherapy [7]. 
Cancer chemotherapy is inevitably damaging to tissues, inducing lipid peroxidation and the 
generation of free radicals such as hydrogen peroxide, hydroxyl- and superoxide-anions [8,9]. 
In this regard, there are reports demonstrating the involvement of free radicals in the 
mediation of cisplatin induced vomiting [10,11]. Generation of free radicals is believed to 
occur at an early stage of treatment, and it is hypothesized to initiate the release of 5-HT from 
enterochromaffin cells in the gastrointestinal tract. The subsequent local activation of 5-HT3 
receptors on abdominal vagal afferents is then thought to make a substantial contribution to 
the mechanism(s) giving raise to CIV 12,13]. Apart from serotonergic receptors [12,14,15], 
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tachykinin [16,17], cannabinoid [18] and DA receptors [19-21] have also attracted interest as 
targets for antiemetic efficacy and it is likely that they all play some role in the central control 
of chemotherapy emetogenesis [18,19,22]. DA D2 receptors, localized in the limbic system, 
hypothalamus, amygdala and also in the brain stem emetic circuitry have received particular 
attention in this respect [23].  
The incapacity of any single antiemetic agent to provide universal efficacious control of 
chemotherapy induced emesis is guiding current research endeavor towards a more wide-
ranging mechanistic approach. Indeed, there is evidence for the involvement of several 
neurotransmitter systems including serotonergic [24,25], dopaminergic [20,21] and 
neurokininergic [16,26] pathways in emetic neuronal circuitry. In light of this, emesis 
induced by anticancer drugs is associated with elevated 5-HT levels in the intestinal mucosa 
as well as the brainstem [27,28] and this is the reason why this neurotransmitter has been 
considered as one of the primary instigators of chemotherapy induced vomiting for quite 
some time [29]. This concept is additionally supported by human and animal studies 
demonstrating increased urinary levels of 5-HIAA [30,31] and 5-HT in intestinal ileal 
segments. 
Bacopa monniera (Linn.) Pennell [syn Bacopa monniera (L) Wettst., Herpestis monniera, 
Gratiola monniera) (family - Scrophulariaceae), NQRZQDV³%UDKPL´LQ,QGLDDQG³-DO1HHP
%RRWL´ LQ 3DNLVWDQ LV D SHUHQQLDO KHUE which is found in marshy places around the world 
including Pakistan[32]. BM has a long history of clinical usage in ayurvedic medicine, 
particularly for the treatment of neuropathic diseases [33,34]. The herb has a number of 
identified pharmacological properties including an ability to block calcium channels [35], and 
to prevent DA receptor-mediated hyperactivity in rats [36]. BM is also well-known to have 
antioxidant activity [37] and is protective against aluminum-induced oxidative stress, which 
is mechanistically similar to the oxidative stress induced by cisplatin [38-41]. 
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In recent years, BM has been studied in an attempt to identify its active constituents. Thus, 
EDFRVLGH ³$´ ZDV VKRZQ WR EH WKH PDMRU FRQVWLWXHQW FRPSULVLQJ D PL[WXUH RI IRXU
compounds, namely bacoside A3 (Fig 1s) bacopaside II, (Fig 2s) bacosaponin C (Fig 2s), and 
jujubogenin isomer of bacosaponin C [42]. Since BM possesses strong antioxidant activity, 
and inhibitory effects on hyperactivity mediated by DA receptors [43], we hypothesized that 
standardized extracts of the herb may have antiemetic properties. The present studies were 
designed, therefore, to investigate any antiemetic potential of the methanolic fraction of BM 
(BM-MetFr), and the bacopaside rich n-butanolic fraction (BM-ButFr), against the cisplatin-
induced retching and vomiting paradigm in the pigeon. In conjunction with this work, 
concentrations of neurotransmitters and their metabolites were evaluated in the brain and 
intestine in order to expose any correlative changes with antiemetogenesis.  
 
 
 
3. Results: 
Cisplatin induced vomiting at doses as low as 5.0 mg/kg, but the response was only seen in 
60 % of pigeons. Cisplatin (7.0 mg/kg) induced a response in all animals tested which 
comprised approximately 43 episodes following a mean latency of ~ 67 min (Figure 1A). 
Increasing the dose further augmented the number of vomiting episodes. Regardless of the 
dose, all responding animals appeared to vomit within the first two hours after cisplatin 
administration, with the most intense period occurring around the first hour (Figure 1B). 
There were no mortalities during 24 h of observation period. 
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Figure 1. (A) Dose-response relationship for cisplatin (2.0 - 10 mg/kg) to induce vomiting 
in pigeons and (B) profile of cisplatin (7.0 mg/kg i.v.) induced vomiting during a 24 hr 
observation period. Data are represented by ± s.e.m. (n = 17). 
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A phytochemical investigation of crude BM-MetFr revealed the presence of saponins, 
flavonoids, tannins and triterpenoids, and the absence of alkaloids and glycosides (Table 1s). 
Table 1(s). Phytochemical screening of BM-MetFr 
Sample 
No 
Test Observation Result 
1 500 mg of BM-MetFr + 2 mL acetic acid + 
1 drop FeCl3 +1 mL H2SO4 
Absence of brown ring 
color at interphase 
Glycosides absent 
2 500 mg BM-0HW)UP/FKORURIRUPĺPL[HG
IRUPLQXWHVĺDPPRQLDVROXWLRQZDVDGGHG 
Absence of light green 
color in upper ammonia 
layer 
Glycosides absent 
3 300 mg BM-0HW)UP/FKORURIRUPĺZDUPHG
IRUPLQXWHVĺVXOSKXULFDFLGZDVDGGHG 
Dark red color in lower 
layer 
Triterpenoids 
present 
4 Aqueous aliquot of BM-MetFr + Ferric chloride 
reagent 
Green black color Tannins present 
5 0.1 g of BM-0HW)UP/GLVWLOOHGZDWHUĺ
)LOWHUHGĺP/ILOWUDWHIHUULFFKORULGHUHDJHQW 
Green black color Tannins present 
6 100mg BM-0HW)UP/HWKDQROĺ)LOWHUĺ
mL filtrate + 0.5N KOH 
Yellowish color Flavonoids present 
7 300 mg BM-0HW)UP/'LVWLOOHGZDWHUĺERLO
IRUPLQXWHVDQGFRROĺYLJRURXVVKDNLQJ 
2.5cm (froth length) Saponins present 
8 0.2 mg BM-MeW)UP/QRUPDOVDOLQHĺ 
ILOWUDWLRQĺP/ILOWUDWHP/RIEORRGĺ 
centrifuge for 5 minutes 
Severe hemolysis Saponins present 
9 0.3 g semisolid BM-MetFr + 2M HCl + Amyl 
DOFRKROĺH[DPLQHWKHDOFRKROLFOD\HU 
No pink color Alkaloids absent 
10 0.1 g Semisolid BM-0HW)U+&OĺILOWUDWLRQ
ĺP/ILOWUDWHGUDJHQGRUII¶VUHDJHQW 
No ppt or turbidity Alkaloids absent 
 
HPLC - UV analysis of the BM methanol fraction provided finger prints for the presence of 
EDFRVLGH ³$´ PDMRU FRPSRQHQWV LQFOXGLQJ EDFRVLGe A3 EDFRVLGH ,, DQG EDFRVDSRQLQ ³&´ 
The total run time was 33 minutes at a flow rate of 0.6 mL using a wavelength of 205 nm 
(Figure 2). The peaks and retention times were first confirmed using standards of the 
respective bacosides. Our results indicated the presence of these bacosides in concentrations 
of 24 ± 1.1 µg/ mg, 4.76 ± 0.03 µg/ mg, 1.23 ± 0.01 µg/ mg (n = 3) for bacoside A3, bacoside 
,,DQGEDFRVDSRQLQ&UHVSHFWLYHO\/LNHZLVHWKHWRWDOFRQFHQWUDWLRQRIEDFRVLGH³$´PDMRU
components in BM-MetFr was 29.99 ± 2.1 µg/ mg of extract. 
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HPLC analysis of the BM n-butanol fraction revealed that it was the bacoside rich fraction 
which contained the EDFRVLGH ³$´ PDMRU FRPSRQHQWV: bacoside A3, bacoside II and 
bacosaponin C in concentrations of 57.91 ± 3.2 µg/ mg, 40.60 ± 0.9 µg/ mg, and 17.23 ± 1.7 
µg/ mg (n = 3), respectively. Similarly, the total concentration of the three major components 
ZLWKLQEDFRVLGH³$´ was 115.74 ± 3.9 µg/ mg in the n-butanol fraction or 38.37 ± 0.7 µg/ gm 
of the dry powder. These values closely correlated with the values reported previously by  
Rauf and others [44]. 
 
Figure 2. HPLC chromatogram VKRZLQJSHDNVRIEDFRVLGH³$´ major components bacoside 
A3 (1), bacoside II (2) and bacosaponin C (3) of standard (I) BM-MrtFr (II) fractions. 
 
In preliminary studies, cisplatin was selected at the dose of 7.0 mg/kg to evaluate the 
antiemetic potential of BM fractions. In these experiments, cisplatin induced vomiting with a 
latency of ~ 67 min and comprising a total of 43 episodes. The BM methanolic fraction (10, 
20 and 40 mg/kg) dose dependently reduced cisplatin induced vomiting (Fig. 3), with the 
highest dose delaying the onset of vomiting by approximately 194 min and reducing the total 
number of episodes to 13.8 ± 2.9 (66.3 % protection) (P < 0.05; Table. 1) during the 24 hr 
observation period. The antiemetic action appeared to last for up to 16 hr (Fig. 4 B). 
I 
II 
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Similarly, the BM n-butanol fraction (5 - 20 mg/kg) reduced cisplatin induced vomiting to 12 
± 2.2 episodes (71.6 % protection) and delayed the onset by approximately 67 min. (Table 1) 
Moreover, the antiemetic action was evident for up to 24 hr in animals treated with 5.0 and 
10 mg/kg (P < 0.001; Fig. 4 C). BM-ButFr (10 mg) proved to be superior as it suppressed the 
response at least in one animal completely. MCP (30 mg/kg) delayed the onset of vomiting 
by 130 min and reduced vomiting during the 24 hr observation period by 48.9 % (P < 0.001). 
Furthermore, unlike BM-MetFr and BM-ButFr, standard metoclopramide (MCP; 30 mg/kg) 
was only found to be significantly effective to reduce vomiting during the first 8 hr period 
(Fig. 4A). 
 
 
 
 
 
 
Figure 3.  Dose response relationship of Bacopa monniera methanolic fraction (BM-MetFr) 
& n-butanolic fraction (BM-ButFr) expressed as % protection against cisplatin induced 
emesis in pigeons. Data represents the mean ± s.e.m (n = 7 ± 8). 
  
10 
 
The antioxidant N-(2-Mercaptoprpionyl) glycine (MPG; 10 mg/kg) attenuated cisplatin 
induced vomiting to 76.5 % (P < 0.001, Table 1 2) and delayed the onset of vomiting by 347 
mins but the vomiting suppression was observed up to 12 h (Fig. 4 A). 
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Figure 4. Vomiting suppression time profile in pigeons (A) standard metoclopramide (MCP; 
30 mg/kg) and N-(2-Mercaptoprpionyl) glycine (MPG; 10 mg/kg) (B) Bacopa monniera 
methanolic fraction (BM-MetFr; 10, 20 and 40 mg/kg) and (C) n-butanolic fraction (BM-
ButFr; 5, 10 and 20 mg/kg) against cisplatin-induced vomiting during a 24 hr observation 
period; each bar represents the mean ± s.e.m of vomiting episodes occurring during 4 hr 
periods (n = 7 - 8). Values significantly different from cisplatin control are denoted as *p < 
0.05, 2*p < 0.01 3*p < 0.001 (ANOVA followed by Tukey post hoc test). 
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Table 1 Effect of BM-MetFr, BM-ButFr, MCP and MPG on cisplatin induced vomiting and 
jerking during a 24 hr observation period in pigeons. 
Drug Treatment Dose & route Pigeons  
n/ vomited 
R + V 
 Mean ± sem 
 
Latency (min) 
Mean ± sem 
Jerks  
Mean ± sem 
 
Wt loss (%) 
Mean ± sem 
Saline + Cisplatin 02ml/kg i.m. + 
07mg/kg i.v 
6/6 47±5.8 74±6.3 647±162 15.3±1.4 
MCP + Cisplatin 30mg/kg i.m. + 
07mg/kg i.v 
8/8 24±1.3** 204±61.3 351±21 12.3±1.4 
MPG + Cisplatin 10mg/kg i.m. + 
07mg/kg i.v 
8/8 11±5.6*** 421±163 225±109* 4.7±1.9** 
Saline + Cisplatin 02ml/kg i.m. 
+ 7mg/kg iv 
6/6 41±5.2 70±6.9 614±115 12±2 
 
BM-MetFr + 
Cisplatin 
10mg/kg i.m. + 
7mg/kg iv 
7/7 27±5.6 270±136 610±161 9.1±1.7 
20mg/kg i.m. + 
7mg/kg iv 
7/7 18±4.4* 156±42 405±167 10.2±1.6 
40mg/kg i.m. + 
7mg/kg iv 
8/8 13±2.9* 264±132 268±108 8.9±1.7 
Saline + Cisplatin 02ml/kg i.m. + 
7mg/kg iv 
5/5 43±5.8 59±5.3 509±67 16.8±2 
 
BM-ButFr + 
Cisplatin 
5mg/kg i.m. + 
7mg/kg iv 
8/8 15±3.2*** 152±35 309±83 8.3±1.6* 
10mg/kg i.m. + 
7mg/kg iv 
7/6 13±3.8*** 142±46 326±137 5.2±1*** 
20mg/kg i.m. + 
7mg/kg iv 
8/8 12±2.2*** 126±14.9 185±38 5.6±1.6*** 
*P < 0.05, **P < 0.01 ***P < 0.001 as compared to cisplatin control (ANOVA followed by 
Tukey post hoc test). 
Control cisplatin treated animals lost ~ 14.7 % of their starting body weight while, animals 
treated with BM-ButFr (5, 10 and 20 mg/kg) as well as MPG (10 mg/kg) lost less than 9 % of 
their starting body weight. These differences compared to the cisplatin control group were 
found to be statistically significant (P < 0.05 - 0.001, Table 1). In the control cisplatin treated 
animals, there were ~ 590 jerking episodes during the 24 hr observation period. Neither 
fraction of BM at those doses studied evoked any effect on any jerking episodes although 
MPG did significantly reduce cisplatin induced jerks (P < 0.05, Table. 2). 
As shown in table 2, neither BM-MetFr (10, 20 and 40 mg/kg) nor BM-ButFr (5.0, 10 and 20 
mg/kg) significantly modified basal levels of the neurotransmitters (NA, DA and 5-HT) or 
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their metabolites (DOPAC, HVA and 5-HIAA) in the area postrema and brain stem or the 
small intestine. However, both BM-MetFr (10, 20 and 40 mg/kg) and BM-ButFr (10 mg/kg) 
significantly decreased (P < 0.01) the level of 5-HIAA in the brain stem. Moreover, intestinal 
NA showed an upsurge (P < 0.001) in response to BM-ButFr (20 mg/kg) (Table 2). 
 
Table 2 Effect of metoclopramide (MCP), BM methanolic fraction (BM-MetFr) or n-
butanolic fraction (BM-ButFr) on basal level of neurotransmitters (ng/mg tissue wet weight) 
and their metabolites in brain areas and the small intestine of pigeons: 
Treatment NA DOPAC DA 5HIAA HVA 5HT 
Area postrema 
Saline 0.610±0.014 0.382±0.111 0.590±0.146 0.158±0.036 0.913±0.095 0.062±0.034 
MCP 30mg 0.023±0.005 0.017±0.006 0.025±0.012 0.005±0.001* 0.121±0.063* 0.023±0.001 
BM-MetFr 10mg 0.058±0.017 0.047±0.010 0.070±0.007 0.017±0.002 0.346±0.047 0.014±0.002 
BM-MetFr 20mg 0.106±0.039 0.168±0.074 0.186±0.066 0.050±0.025 0.238±0.117 0.054±0.034 
BM-MetFr 40mg 0.336±0.174 0.092±0.025 0.216±0.089 0.032±0.011 0.476±0.151 0.035±0.014 
BM-ButFr 05mg 0.261±0.031 0.043±0.010 0.044±0.105 0.207±0.041 0.426±0.072 0.146±0.050 
BM-ButFr 10mg 0.044±0.023 0.115±0.034 0.277±0.054 0.047±0.006 0.356±0.098 0.020±0.004 
BM-ButFr 20mg 0.909±0.165 0.313±0.087 0.802±0.210 0.066±0.028 0.854±0.440 0.105±0.057 
Brain stem 
Saline 0.094±0.022 0.060±0.020 0.175±0.078 0.060±0.021 0.060±0.016 0.010±0.003 
MCP 30mg 0.119±0.033 0.027±0.006 0.044±0.012 0.007±0.001*** 0.066±0.031 0.019±0.002 
BM-MetFr 10mg 0.040±0.020 0.017±0.006 0.063±0.027 0.011±0.003** 0.051±0.025 0.037±0.019 
BM-MetFr 20mg 0.147±0.091 0.052±0.036 0.058±0.040 0.005±0.001** 0.037±0.021 0.019±0.005 
BM-MetFr 40mg 0.020±0.009 0.035±0.002 0.022±0.018 0.003±0.001*** 0.022±0.015 0.010±0.002 
BM-ButFr 05mg 0.108±0.010 0.015±0.001 0.698±0.407 0.067±0.014 0.021±0.003 0.167±0.014*** 
BM-ButFr 10mg 0.054±0.016 0.021±0.006 0.046±0.011 0.011±0.001** 0.032±0.022 0.011±0.002 
BM-ButFr 20mg 0.156±0.097 0.084±0.050 0.178±0.110 0.031±0.001 0.243±0.077*** 0.041±0.005 
Intestine 
Saline 0.194±0.059 0.067±0.020 0.090±0.064 0.076±0.058 0.056±0.025 0.049±0.016 
MCP 30mg 0.138±0.039 0.054±0.025 0.059±0.018 0.097±0.022 0.198±0.102 0.062±0.013 
BM-MetFr 10mg 0.117±0.047 0.106±0.047 0.089±0.045 0.061±0.016 0.069±0.032 0.236±0.103 
BM-MetFr 20mg 0.114±0.040 0.110±0.053 0.329±0.125 0.077±0.014 0.032±0.012 0.158±0.022 
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BM-MetFr 40mg 0.015±0.006 0.026±0.003 0.011±0.005 0.028±0.004 0.013±0.009 0.044±0.007 
BM-ButFr 05mg 0.204±0.033 0.005±0.001 0.123±0.052 0.268±0.068** 0.077±0.025 0.848±0.187*** 
BM-ButFr 10mg 0.290±0.083 0.144±0.109 0.289±0.196 0.121±0.028 0.247±0.107 0.106±0.026 
BM-ButFr 20mg 1.328±0.271*** 0.090±0.044 0.244±0.162 0.051±0.014 0.142±0.052 0.145±0.036 
*P < 0.05, **P < 0.01, ***P < 0.001 as compared to cisplatin control (ANOVA followed by 
Tukey post hoc analysis; n = 6 - 8). 
 
Cisplatin treatment significantly increased (P < 0.001) the concentration of 5-hydroxy 
tryptamine (5-HT) in the brain stem and small intestine as compared to basal control levels, 
while no significant increase was observed in the area postrema (Table 3). Treatment with 
MCP (30 mg/kg) did not modify the concentrations of NA, DOPAC, DA, 5-HIAA and HVA 
in either brain area or the intestine, but it did significantly decrease (P < 0.001) the 
concentration of 5-HT in the brain stem and intestine as compared to the cisplatin control 
(Table 3). In addition to its inhibitory effects on 5-HT, MCP also decreased the 5-HIAA 
concentration in the area postrema (Table 4), while no significant change was observed in the 
brain stem or small intestine (Tables 3 and 4). 
BM-MetFr (10, 20 and 40 mg/kg) and BM-ButFr (5.0, 10 and 20 mg/kg) treatments reduced 
the concentration of 5HT in the brain stem (P < 0.001) and intestine (P < 0.001, Table 3) as 
compared to cisplatin control, without any significant effects on NA, DOPAC, HVA and 
5HIAA. Furthermore, no significant alteration was observed in the area postrema. 
 
 
 
 
15 
 
 
Table 3  Effect of standard metoclopramide (MCP), BM methanolic fraction (BM-MetFr) or 
n-butanolic fraction (BM-ButFr) on neurotransmitters (ng/mg tissue wet weight) and their 
metabolites in brain areas and small intestine 3 hours after cisplatin treatment in pigeons: 
Treatment NA DOPAC DA 5HIAA HVA 5HT 
 
  Area postrema    
Saline 0.571±0.072 0.389±0.108 0.543±0.130 0.290±0.059 1.374±0.485 0.011±0.001 
Cisplatin 1.411±1.160 0.299±0.132 0.073±0.023 0.211±0.079 3.859±3.373 0.316±0.093 
MCP 30mg 0.116±0.078 0.106±0.040 0.223±0.103 0.024±0.005 0.069±0.045 0.023±0.005 
BM-MetFr 10mg 0.537±0.144 0.129±0.032 0.245±0.066 0.035±0.010 1.301±0.515 0.020±0.009 
BM-MetFr 20mg 0.682±0.297 0.358±0.222 0.844±0.585 0.109±0.061 0.447±0.215 0.042±0.009 
BM-MetFr 40mg 0.250±0.082 0.206±0.009 0.699±0.143 0.035±0.007 0.393±0.092 0.027±0.006 
BM-ButFr 05mg 0.960±0.146 0.492±0.088 0.558±0.128 0.238±0.039 1.603±0.341 1.990±1.646 
BM-ButFr 10mg 0.445±0.098 0.110±0.031 0.197±0.058 0.038±0.017 0.319±0.217 0.025±0.011 
BM-ButFr 20mg 0.109±0.032 0.058±0.012 0.122±0.020 0.025±0.006 1.317±0.414 0.020±0.003 
 
  Brain stem    
Saline 0.071±0.004 0.073±0.012 0.069±0.023 0.017±0.015 0.022±0.010 0.031±0.002 
Cisplatin 0.080±0.019 0.130±0.098 0.032±0.001 0.049±0.013 0.016±0.008 0.138±0.018### 
MCP 30mg 0.044±0.016 0.015±0.005 0.018±0.011 0.041±0.001 0.042±0.002 0.021±0.001*** 
BM-MetFr 10mg 0.152±0.050 0.053±0.021 0.011±0.025 0.016±0.004 0.102±0.028 0.012±0.004*** 
BM-MetFr 20mg 0.145±0.071 0.057±0.021 0.093±0.030 0.025±0.005 0.220±0.062 0.007±0.001*** 
BM-MetFr 40mg 0.132±0.007 0.097±0.006 0.797±0.086 0.025±0.003 0.222±0.128 0.018±0.001*** 
BM-ButFr 05mg 0.037±0.010 0.013±0.001 0.010±0.001 0.021±0.004 0.024±0.001 0.090±0.020* 
BM-ButFr 10mg 0.068±0.011 0.139±0.126 0.052±0.040 0.055±0.001 0.215±0.077 0.017±0.002*** 
BM-ButFr 20mg 0.037±0.004 0.083±0.014 0.076±0.016 0.018±0.001 0.289±0.023 0.006±0.001*** 
 
  
 Intestine    
Saline 0.374±0.184 0.105±0.040 0.137±0.054 0.410±0.269 0.054±0.022 0.044±0.016 
Cisplatin 0.208±0.032 0.015±0.002 0.002±0.000 0.285±0.020 0.035±0.003 0.821±0.137### 
MCP 30mg 0.119±0.044 0.060±0.059 0.164±0.127 0.033±0.005 0.086±0.030 0.045±0.006*** 
BM-MetFr 10mg 0.152±0.050 0.053±0.021 0.116±0.025 0.016±0.004 0.102±0.028 0.012±0.004*** 
BM-MetFr 20mg 0.229±0.116 0.048±0.031 0.066±0.044 0.028±0.004 0.348±0.185 0.009±0.001*** 
BM-MetFr 40mg 0.235±0.066 0.101±0.036 0.530±0.235 0.082±0.010 0.290±0.112 0.048±0.021*** 
BM-ButFr 05mg 0.051±0.024 0.016±0.007 0.040±0.023 0.208±0.026 0.040±0.026 0.420±0.069*** 
BM-ButFr 10mg 0.087±0.026 0.024±0.013 0.041±0.026 0.021±0.008 0.498±0.353 0.005±0.002*** 
BM-ButFr 20mg 0.238±0.036 0.105±0.066 0.112±0.035 0.023±0.004 0.784±0.291 0.027±0.008*** 
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Neurotransmitter or metabolite levels significantly different from cisplatin control are 
denoted by *P < 0.05, ***P < 0.001, while Values significantly different as from basal levels 
are denoted by ###P< 0.001 (ANOVA followed by Tukey post hoc analysis; n = 6 - 8). 
 
Cisplatin increased the level of DA highly significantly (P < 0.001) in the area postrema, 
while no significant increase was observed in the brain stem or small intestine (Table 4 5). 
Concentration levels of 5-HT were also raised in the brain stem (P < 0.05) and small intestine 
(P < 0.001), without affecting NA, DOPAC, 5-HIAA or HVA levels in the brain stem and 
intestine or 5-HT in the area postrema (Table 4). Treatment with standard metoclopramide 
(MCP; 30 mg/kg) significantly decreased the upsurge of DA in the area postrema (P < 0.001) 
and brain stem (P < 0.01; Table 4).  
Both fractions of BM i.e. methanolic (BM-MetFr; 10, 20 and 40 mg) and butanolic (BM-
ButFr; 5, 10 and 20 mg) were found to be highly effective in reducing the DA concentration 
(P < 0.001) in the area postrema with respect to the cisplatin control. A similar effect was 
also seen in the brain stem but with variable statistical significance (P < 0.05-0.001; Table 4 
5). However, BM-MetFr (20 and 40 mg/kg) failed to attenuate DA concentrations in the brain 
stem (Table 4). Moreover, in the small intestine, there was a significant reduction (P < 0.001) 
in the levels of 5-HT in response to the BM methanolic and butanolic fractions to all the 
doses tested, with the exception of BM-MetFr (40 mg/kg) and BM-ButFr (5.0 mg/kg). 
Furthermore, BM-MetFr (40 mg/kg) and BM-ButFr (20 mg/kg) significantly (P < 0.05) 
decreased the level of 5-HIAA in the area postrema (Table 4). 
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Table 4 Effect of standard metoclopramide (MCP), BM methanolic fraction (BM-MetFr) or 
n-butanolic fraction (BM-ButFr) on neurotransmitters (ng/mg tissue wet weight) and their 
metabolites in brain areas and the small intestine at 18 hours after cisplatin treatment in 
pigeons: 
Treatment NA DOPAC DA 5HIAA HVA 5HT 
 
  Area postrema    
Saline 0.599±0.084 0.458±0.160 0.535±0.168 0.347±0.084 1.763±0.743 0.012±0.001 
Cisplatin 0.247±0.059 0.022±0.008 13.43±4.528### 0.164±0.042 0.395±0.104 0.147±0.044 
MCP 30mg 0.161±0.070 0.052±0.023 0.048±0.024*** 0.021±0.002* 0.276±0.157 0.010±0.003 
BM-MetFr 10mg 0.493±0.166 0.150±0.019 0.365±0.061*** 0.059±0.004 1.164±0.272 0.057±0.014 
BM-MetFr 20mg 0.467±0.208 0.193±0.058 0.350±0.063*** 0.053±0.010 0.576±0.202 0.046±0.009 
BM-MetFr 40mg 0.903±0.170 0.075±0.018 0.155±0.033*** 0.030±0.004* 0.198±0.045 0.025±0.007 
BM-ButFr 05mg 0.808±0.104 0.765±0.152 0.746±0.254*** 0.223±0.045 1.177±0.248 0.750±0.243 
BM-ButFr 10mg 0.233±0.055 0.039±0.031 0.062±0.044*** 0.074±0.032 1.056±0.403 0.037±0.015 
BM-ButFr 20mg 0.215±0.036 0.068±0.023 0.146±0.026*** 0.024±0.006* 0.901±0.255 0.018±0.003 
 
  Brain stem    
Saline 0.069±0.005 0.086±0.017 0.094±0.033 0.018±0.021 0.025±0.017 0.011±0.006 
Cisplatin 0.068±0.003 0.021±0.001 0.258±0.057 0.036±0.003 0.019±0.003 0.121±0.008# 
MCP 30mg 0.101±0.094 0.001±0.001 0.013±0.013** 0.014±0.004 0.082±0.052 0.014±0.002 
BM-MetFr 10mg 0.074±0.066 0.054±0.050 0.021±0.019** 0.035±0.006 0.371±0.161 0.030±0.005 
BM-MetFr 20mg 0.241±0.146 0.073±0.033 0.135±0.126 0.024±0.008 0.168±0.051 0.033±0.008 
BM-MetFr 40mg 0.384±0.139 0.064±0.015 0.109±0.040 0.015±0.006 0.243±0.100 0.110±0.096 
BM-ButFr 05mg 0.072±0.002 0.030±0.002 0.007±0.002*** 0.034±0.002 0.010±0.001 0.141±0.005 
BM-ButFr 10mg 0.054±0.024 0.025±0.025 0.021±0.016** 0.018±0.003 0.390±0.101 0.007±0.001* 
BM-ButFr 20mg 0.128±0.033 0.147±0.030 0.080±0.035* 0.025±0.003 0.216±0.090 0.025±0.003 
 
  Intestine    
Saline 0.288±0.237 0.060±0.015 0.058±0.021 0.656±0.403 0.059±0.031 0.045±0.026 
Cisplatin 0.228±0.027 0.005±0.001 0.397±0.173 0.390±0.044 0.053±0.006 0.588±0.163### 
MCP 30mg 0.177±0.078 0.011±0.003 0.020±0.010 0.022±0.005 0.433±0.384 0.030±0.006*** 
BM-MetFr 10mg 0.405±0.129 0.281±0.130 0.064±0.330 0.039±0.019 1.112±0.685 0.058±0.024*** 
BM-MetFr 20mg 0.336±0.144 0.309±0.146 0.122±0.051 0.114±0.023 0.095±0.031 0.188±0.035** 
BM-MetFr 40mg 0.545±0.254 0.220±0.104 0.159±0.067 0.113±0.034 0.111±0.043 0.317±0.072 
BM-ButFr 05mg 0.152±0.027 0.075±0.034 0.069±0.029 0.227±0.028 0.221±0.131 0.641±0.067 
BM-ButFr 10mg 0.103±0.039 0.031±0.031 0.090±0.067 0.066±0.028 1.737±0.360 0.017±0.004*** 
BM-ButFr 20mg 0.294±0.068 0.235±0.073 0.333±0.161 0.126±0.010 0.594±0.301 0.140±0.024*** 
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 Neurotransmitter and metabolites values significantly different from cisplatin control are 
denoted by *P < 0.05 **P < 0.01 ***P < 0.001, while values significantly different from basal 
level are indicated by #P < 0.05 ###P < 0.001 (ANOVA followed by Tukey post hoc analysis; 
n = 6 - 8). 
Discussion: 
The pigeon is a species that has been used in emesis research for many years and it 
responds to a number of different emetic stimuli including cardiac glycosides [45,46] ), 
reserpine [47], sigma receptor ligands [48], and the chemotherapeutic drugs 
cyclophosphamide [49] and cisplatin [50,51]. In terms of its translational value, it can be 
used to assay the antiemetic activity of several classes of drug including 5-HT3 and NK1 
receptor antagonists [16,52] and the glucocorticoids [53]. Investigators have studied 
lower doses of cisplatin (4.0 mg/kg), where the emetic response can continue for several 
days and is mediated by vagal and reserpine-sensitive monoaminergic systems [16,54]. In 
our studies, we used cisplatin at a dose of 7.0 mg/kg and found a reproducible emetic 
response in all animals for 24 hours without lethality. We also observed that cisplatin at 
the lower dose of 5.0 mg/kg induced vomiting in 60 % of the animals and this slightly 
higher dose response relationship with respect to previous studies may be attributed to 
species differences, environmental factors and food. There is no mechanistically distinct 
acute or delayed phase of chemotherapy induced vomiting in the pigeon, even though 
previous studies have monitored emesis for up to 72 hours [16,53]. In our studies, we 
observed the animals for 24 hours to comply with the ethical use of animals. 
  
Our study is the first to report the antiemetic activity of BM  in the pigeon model and this 
indicates that the antiemetic activity should be evaluated in other animal models such as 
the dog [55] and ferret [56] where delayed emesis can be observed. The major finding of 
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the present study was that both methanolic and n-butanolic extracts of BM possessed 
antiemetic activity with an efficacy and duration of action superior (MCP). MCP, a D2 
and 5-HT3 receptor antagonist with 5-HT4 receptor agonist properties, was chosen as the 
reference standard drug [57]. The dose of MCP that we selected was higher than that 
required to antagonize cisplatin-induced emesis in other species [58], and was based on a 
previous study in the pigeon showing activity against reserpine induced emesis [59].  
The anti-emetic activity of BM-MetFr prompted the screening of the bacoside rich n-
butanolic fraction (BM-ButFr), which proved to be more potent than BM-MetFr 
indicating a potential inhibitory role of bacosides against vomiting induced by cisplatin. 
Bacosides have been reported to exhibit anticancer effects [60], potent antioxidant 
activity [37], and neuroprotective properties against aluminum induced oxidative stress 
[38,39]. Furthermore, there is a close mechanistic resemblance between the oxidative 
stress induced by aluminium and cisplatin in the cellular cytoplasm and mitochondria 
[38,41]. In the long term, BM can restore the normal antioxidant defense mechanism of 
the body [61], which may be useful in protection against delayed emesis. It is possible 
that this action could further contribute to its antiemetic mechanism of action, since the 
antioxidant MPG is effective against cisplatin induced vomiting in the pigeon and this 
finding has also been reported in other species [10,13]. Nevertheless, the efficacious and 
potent antiemetic nature of BM-ButFr, compared to MCP, may be putatively attributed to 
the bacoside A components namely bacoside A3, bacoside II and bacosaponin C which 
are detectable in the plant extract (n-butanolic fraction) in concentrations up to 57.91 ± 
3.2 µg/ mg, 40.60 ± 0.9 µg/ mg, and 17.23 ± 1.7 µg/ mg, respectively. Likewise the three 
major components of bacoside A at a total concentration of 115.74 ± 3.9 µg/ mg were 
identified in BM-ButFr or 38.37 ± 0.7 µg/ gm of the dry powder, which concurs with an 
earlier report [44]. The presence of steroidal saponins, including bacoside A, which along 
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with bacopaside 1 constituted more than 96%w/w of the total saponins of  B. monniera 
[62], are able to cross the blood brain barrier and modulate enzyme activities, proteins, 
and neurotransmitters in different brain regions [63-67]. 
 
Treatment with BM extracts decreased the concentration of 5-HT in the brain stem and 
intestine (Table 3) three hours following cisplatin administration. The BM herb itself has 
been proved to be antioxidant [68] and this is one of the probable mechanisms by which 
BM-MetFr and BM-ButFr reduced the intestinal and brain stem concentration of 5-HT in 
comparison with MCP (Table 3). Thus, the decrease in 5-HT concentration may arise via 
protection of enterochromaffin (EC) cells from cisplatin-induced oxidative damage at the 
intestinal level, and this is an important consideration because 95 % of 5-HT is present in 
the EC cells of the gastrointestinal mucosa [31]. The decreases in 5-HT induced by both 
BM-MetFr and BM-ButFr in the brain stem and intestine are highly relevant to antiemetic 
propensity. In this context, EC cell 5-HT release can subsequently stimulate 5-HT3 
receptors on vagal afferent fibres triggering an emetogenic 5-HT increase in the area 
postrema [69] and conversely, a 5-HT level decrement would be antiemetic.   
Furthermore, there is evidence of a comparatively high density of 5-HT3 receptors in the 
NTS [70,71] and DMV [72] which would support the contention that BM administration 
would be antiemetic. 
BM treatment had no effect on the levels of neurotransmitters (NA, DA and 5-HT) or 
their metabolites (DOPAC, HVA and 5-HIAA) in the area postrema during acute time (3 
hour after cisplatin administration). However, the area postrema is thought to be involved 
in the delayed phase of vomiting because ablation of this medullary region suppresses it 
[73]. Furthermore, in the brain vomiting circuitry, dopamine receptors also located in the 
area postrema are regarded as the source of both morphine and apomorphine emesis [74-
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76]. Conversely, 5-HT is reported to be the primary mediator of the acute cisplatin 
vomiting response via the NTS [56,77] so it is possible that BM influences this acute 
phase.  
 
Literature regarding the delayed phase of cisplatin induced vomiting is indicative of 
overlapping mechanisms involving the role of substance P and DA [78,79]. BM has been 
shown to inhibit hyperactivity and dopamine receptor supersensitivity induced by 
morphine as well as apomorphine climbing behavior in rats [36,80] and comparable 
findings have also been reported by our laboratory [81]. In the present study, cisplatin 
treatment resulted in a significant increase (p<0.001) in  DA concentration 18 h post 
administration in the area postrema and a statistically nonsignificant effect in the 
concentration of DA in the intestine (Table 4). The magnitude of DA upsurge at the level 
of the area postrema was far greater than in the intestine, as the area postrema is 
considered to be involved in delayed sickness [73] and is the source of vomiting induction 
by morphine and apomorphine via the dopaminergic system [74]. Tanihata et al. [54] also 
observed a slight increase in DA concentration induced by cisplatin (4 mg/kg) in the 
small intestine when compared to other treatments in pigeons. In another study on minks, 
Qian and others [82] demonstrated a statistically significant increase (p<0.05) in DA 
concentration in the area postrema and ileum after cisplatin treatment (7.5 mg/kg). In a 
study in the least shrew animal model, cisplatin (10 mg/kg) increased (p<0.05) the DA 
concentration during both phases of vomiting while duodenal DA levels were unaffected 
[83].  In contrast, BM-MetFr and BM-ButFr treatments decreased the dopamine upsurge 
in the area postrema and brain stem (Table 4). These findings provide evidence in favor 
of an antiemetic effectiveness of BM extracts for prolonged protection against cisplatin 
emetogenesis which is contingent upon DA function. Such antidopaminergic activity of 
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BM extracts is entirely complementary to previously reported neurochemical studies from 
this laboratory [43]. Furthermore, the BM- induced decrease in 5-HIAA and 5-HT levels 
in the area postrema and intestine 18 h after cisplatin treatment may well be the 
manifestation of additional mechanism(s) involved in the anti-emetic properties of the 
herbal extracts. 
 
Both BM extracts failed to alter basal levels of neurotransmitters or their metabolites in 
the brain stem with the exception of a fall in 5-HIAA. Consequently, it might be argued 
that such comparative selectivity of their neurochemical activity for the area postrema and 
small intestine is an indicator of prospective safety and tolerability. Apart from a possible 
application in emetogenic chemotherapy, BM has other additional properties including 
antinociceptive activity [84,85] and efficacy in acute stress or chronic unpredictable stress 
[64] both of which may be advantageous  in patients undergoing cancer chemotherapy 
[86]. 
In conclusion, the present study has disclosed that BM extracts provide a long lasting 
suppression of vomiting induced by cisplatin, whereby anti-serotonergic and anti-
dopaminergic activities occur over early and late emetic phases in a continuum. Thus 
during the early phase, anti-serotonergic effects predominate while in the later phase there 
is an anti-dopaminergic aftermath. BM-BuFr, which is rich in bacoside A, showed 
superior antiemetic activity, thus implicating the role of bacoside A in the antiemetic 
activity of BM, though further studies are required ti investigate the involvement of its 
individual components. Moreover, BM is known to be non-addictive, and has a tolerable 
safety profile making it worthy of further investigation as an anti-emetic agent, or at least 
an adjunct, against cisplatin induced vomiting in other animal models as well as in man. 
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Materials and Methods: 
 Animals: 
Pigeons of either sex (mixed breed, Department of Pharmacy, University of Peshawar, 
Pakistan) weighing between 250 - 350g were used. They were housed in groups of eight at 22 
- Û&XQGHUDh:12h light/dark cycle and had free access to food (locally available food; 
millet + wheat) and water before and during experimentation. All the experimental 
procedures were approved by the Ethical Committee, Department of Pharmacy, University of 
Peshawar (Ref. No 5/pharm) and are in accordance with the UK animal scientific procedure 
Act, 1986. 
Drugs and chemicals: 
Cisplatin ( (Korea United Pharm. Inc. Korea), metoclopramide (MCP; 
GlaxoSmithKline Pakistan Ltd.), N-(2-Mercaptoprpionyl) glycine (MPG ; Sigma 
Aldrich Germany), 1$, DOPAC , '$, 5HIAA , HVA , 5-HT 
 (Acros Organics, Belgium), HPLC grade acetonitrile (99.9%), methanol (99.9%) and 
1-octane sulphonic acid sodium salt (>98%) (Fisher scientific U.K), sodium dihydrogen 
orthophosphate sodium (99%) and EDTA  (Merck), Bacoside A3 , Bacoside II 
and Bacosaponin C  (a gift from Prof. Dr. Ikhlas Khan, the National Center 
for Natural Products Research, University of Mississippi USA), commercial grade methanol, 
n-hexane, n-butanol and acetone (Haq Chemicals Peshawar).  
Extraction of Bacopa monniera and fractionation: 
The plant was collected in November from Rumalee stream near Quaid-e-Azam University, 
Islamabad Pakistan. The plant was authenticated by Prof. Dr. Muhammad Ibrar, Department 
of Botany, University of Peshawar and a specimen was deposited in the herbarium (Voucher 
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No 7421). The aerial parts were separated, shade dried and coarsely powdered. A 1 kg sample 
of the resultant plant material was extracted with n-hexane (6L), and then with acetone (5L) 
to remove fats and chlorophyll-type pigments. The product was then extracted using 
commercial grade methanol (1.5L) in a soxhelet apparatus to yield 28 g. The resultant 
material was subfractionated to obtain the n-butanol fraction (yield 1.6 grams), which is 
reported to be rich in bacosides [87]. The methanolic fraction (BM-MetFr) and the bacoside 
rich n-butanolic fraction (BM-ButFr) of the plant were dissolved in distilled water prior to 
antiemetic testing. 
Gross phytochemical investigation: 
BM was screened preliminarily, for the presence of glycosides [88] namely triterpenoids [89], 
tannins , flavonoids , saponins [90] and alkaloids [89,91]. 
Quantification of Bacosides in BM methanol and n-butanol fractions: 
High performance liquid chromatography coupled with UV was used for the quantification of 
%DFRVLGH³$´PDMRUFRPSRQHQWVEDFRVLGH$3, bacoside II and bacosaponin C using our own 
method with slight modification [44]. Briefly, 5mg of BM-MetFr or BM-ButFr was dissolved 
in 5mL of HPLC grade methanol, centrifuged at 3000 rpm for 10 minutes and filtered 
through 0.45µ filter. 300µL of the filtered solution was further diluted with methanol to make 
up a volume of 5mL. HPLC system equipped with LC-20AT double pumps (Shimadzu, 
Japan), a rheodyne injector of 20µL loop, SPD-20A UV detector (PDA) and purospher C18 
column (250mm × 4.6mm × 4µm particle size) was used. The mobile phase consisted of 0.2 
% phosphoric acid and acetonitrile (62:38, v/v). The mobile phase PH was adjusted to 3 using 
3M NaOH. 
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Drug formulation: 
Cisplatin was dissolved in normal saline by heating up to 60oC, cooled to 40 - 45oC and 
immediately administered. The methanolic and n-butanolic fractions of BM were dissolved in 
normal saline by gentle agitation and sonicated to get a clear solution for in vivo 
administration. 
Drug administration: 
Cotton wool and methylated spirits were used to sterilize the skin prior to drug 
administration. Intravenous and intramuscular administrations were done through the brachial 
wing vein and chest muscle, respectively using Neoject 2ml non-pyrogenic syringes with 
sharp painless needles (27G × 1/2" for the i.v. route, and 23G × 1" for the i.m. route). 
Immediately, after the last injection, the animals were put back in the specially designed 
confining/observation cages and the incident counts of R + V and latency to first vomit were 
recorded for 24 h. At the end of experiment, body weight loss was calculated. Subsequently, 
the animals were decapitated to terminate the experiment. 
Antiemetic assay: 
On the day of the experiment, the pigeons were placed in individual cages specially designed 
for video observation. A preliminary study was conducted to evaluate the optimal dose of 
cisplatin to induce vomiting. Thus, cisplatin (2.0 ± 10mg/kg) was administered intravenously 
via the brachial wing vein at 0 minutes (t = 0) [54]. The behavior of each pigeon was then 
recorded for 24 h. Food and water were available during the observation period and each 
animal was used only once. The response with or without oral expulsion was considered as 
one vomiting episode [92]. The latency to first vomit and the number of vomiting episodes 
were recorded.  A vomiting episode was considered to be completed when the pigeon 
adopted relaxed posture. Jerking episodes, which are indicative of vomiting intensity, were 
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also recorded. In subsequent antiemetic studies, cisplatin was used at 7.0 mg/kg, i.v. to elicit 
an emetic response to enable assessment of the potential antiemetic action of the BM 
fractions, MCP and MPG. In these studies, BM-MetFr, BM-ButFr, MCP and MPG or 
respective vehicles, were administered 30 minutes before cisplatin administration. 
Tissue sampling for neurotransmitters analysis: 
Two discrete parts of the brain (brain stem and area postrema) as well as the intestinal 
samples 5 ± 6 cm from the pylorus were used for the neurotransmitter analyses and the effects 
of BM-MetFr, BM-ButFr and MCP were investigated. At the end of each experiment, 
animals were decapitated and the brain areas and intestinal samples were rapidly dissected 
and placed on an ice cold plate (0oC). The dissection of brain parts was carried out according 
to the atlas of Karten and Hodos [93] and Henri M. Duvernoy [94]. After decapitation of 
experimental animals, the dorsal surface of the skull was exposed by making an incision 
along the midline, and the temporal muscles were stripped off to expose the skull bone. After 
exposing the skull, bones and meninges were carefully removed in such a way to expose the 
brain hemispheres, especially to make the brain stem prominent from the ventral aspect. The 
long strip of capillaries stretching from the obex on the median line to the lateral angles of the 
fourth ventricle (area postrema) was dissected followed by dissection of the brain stem. 
Jejunal samples of about 2 cm were rapidly removed and washed with ice cold saline. The 
collected samples were rapidly frozen on an ice plate and stored at -80oC until analysis. 
 Determination of neurotransmitters and their metabolites: 
Tissue samples were homogenized in cold 0.2 % perchloric acid (PCA) at 5000 rpm with the 
help of Teflon glass homogenizer (Wise stir HS 30 E). After centrifugation (Centurion UK) 
at 12000 g/min (4oC) the samples were filtered through a 0.45 micron filter. 
Neurotransmitters and their metabolites were analyzed using a high performance liquid 
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chromatography system (HPLC, Shimadzu, Japan) coupled with electrochemical detection 
(ECD, ESA Coulochem III model 5300), a pump (model LC-20AT), and an analytical 
column (Teknokroma 3 x 150, 3um). The mobile phase consisted of 94 mM sodium 
dihydrogen orthophosphate, 40 mM Citric acid, 2.3 mM sodium 1-octane sulphonic acid, 50 
uM EDTA, and 10 % acetonitrile (pH 3). The flow rate was maintained at 0.6 mL/min. The 
standards used were NA hydrochloride, DOPAC, DA hydrochloride, 5HIAA, HVA and 5-
HT. The HPLC method was reproducible and all the neurotransmitters and their metabolites 
were separated within 13 minutes. 
Statistical analysis: 
The differences between means were evaluated using a one way analysis of variance 
(ANOVA) followed by Tukey¶V multiple comparison tests. P<0.05 was considered as 
statistically significant. The animals which showed complete suppression of R + V were not 
included in statistical analyses for latency. Data represent the mean ± SEM unless otherwise 
indicated. 
Supporting information 
The structures of the major bioactive components of bacoside A and details of the 
phytochemical screening of BM-MetFr are available as Supporting Information 
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